In this article, ACROBiosystems discusses how the complement cascade and it's various components could potentially be leveraged for therapeutic potential in COVID-19, cancer and general inflammation.

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

To investigate, first author Scott-Hewitt isolated synaptosomes from wild-type mice and immunoprecipitated C1q from them, checking to see what else came along for the ride. Unexpectedly, C1q from year ...